深圳市理邦精密仪器股份有限公司 投资者关系活动记录表 | 投资者关 | □特定对象调研 □分析师会议 | | --- | --- | | 系活动类 | □媒体采访 ■业绩说明会 | | 别 | □新闻发布会 □路演活动 | | | □现场参观 □其他 | | 参与单位 | | | 名称及人 | 线上参与公司 2024 年度网上业绩说明会的全体投资者 | | 员姓名 | | | 时间 | 2025 年 5 月 19 日 15:00-17:00 | | 地点 | 价值在线（https://www.ir-online.cn/）网络互动 | | 上市公司 | 董事长、总裁：张浩 | | 接待人员 | 董事、副总裁、董事会秘书、财务负责人：祖幼冬 | | 姓名 | 独立董事：郑全录 | | | 1、请问公司领导，目前的业务增长情况如何？未来有哪些具体的市场扩展 | | 投资者关 | 计划？ | | 系活动主 | 公司目前经营状况正常，各项业务按计划有序推进，具体经营数据和业务信 | | 要内容介 | 息请参考公司定期披露的公告。 关于未来市场拓展，一方面，公司将继续深耕 | | 绍 | 国内市场和夯实国内基础，挖掘潜在 ...

Core Viewpoint - The high-end medical device industry in Shenzhen is a significant indicator of national manufacturing capability and technological development, with a projected revenue of 200 billion yuan by 2025, highlighting its importance in the global medical device market [1]. Group 1: Industry Overview - Shenzhen's medical device output reached 99 billion yuan in 2023, accounting for approximately 10% of the national total, with exports also around 10% [1]. - The city is home to leading companies like Mindray Medical and BGI, which are recognized among the top 100 global medical device firms [1]. Group 2: Technological Advancements - The brain-computer interface technology developed by Shenzhen Ruihan Medical has shown significant promise in rehabilitation, with patients experiencing better recovery outcomes compared to traditional methods [2][3]. - Ruihan Medical's brain-computer interface rehabilitation robot system is the first commercialized product of its kind globally, with over 100 patents and a focus on practical application [3]. Group 3: Collaborative Innovation - The National High-Performance Medical Device Innovation Center in Shenzhen is addressing core technological challenges in the medical device sector through collaborative projects with key enterprises [6][7]. - The center has successfully developed a 5.0T whole-body MRI system, marking a significant breakthrough in high-field MRI technology [6]. Group 4: Market Dynamics - The medical device industry in Shenzhen is characterized by a "chain development" model, where breakthroughs in technology stimulate growth across the entire supply chain [8]. - Companies like Mindray Medical and Libang Instruments have successfully disrupted international monopolies in their respective fields, leading to increased domestic production capabilities [9][10]. Group 5: Spatial and Policy Support - Shenzhen's medical device industry faces challenges such as limited industrial space, prompting local governments to create favorable conditions for business growth [11][12]. - The city has introduced comprehensive support measures for the medical and pharmaceutical sectors, aiming to solidify its position as a leading hub for medical device innovation [13].

深圳市理邦精密仪器股份有限公司 证券代码：300206 证券简称：理邦仪器 公告编号：2025-027 深圳市理邦精密仪器股份有限公司 2024年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示 1、本次股东大会未出现否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开情况 1、会议召开时间： 现场会议时间：2025 年 5 月 15 日（星期四）下午 15:30。 网络投票时间：2025 年 5 月 15 日；其中，通过深圳证券交易所交易系统进 行网络投票的具体时间为：2025 年 5 月 15 日上午 9:15-9:25、9:30-11:30，下午 13:00-15:00；通过深圳证券交易所互联网投票系统进行网络投票的具体时间为： 2025 年 5 月 15 日上午 9:15 至下午 15:00 期间的任意时间。 深圳市理邦精密仪器股份有限公司 6、会议召开方式：现场投票与网络投票相结合的方式 7、会议的召集、召开与表决程序符合《公司法》《上市公司股东会规则》 《深圳证券交易所股票上市规则》及《公 ...

北京市中伦（深圳）律师事务所 关于深圳市理邦精密仪器股份有限公司 2024年度股东大会的 法律意见书 致：深圳市理邦精密仪器股份有限公司 根据《中华人民共和国公司法》（下称"《公司法》"）、《上市公司股东会规则》 （下称"《股东会规则》"）等有关法律法规的规定及公司现行章程（下称"《公司 章程》"）的有关规定，北京市中伦（深圳）律师事务所（下称"本所"）接受深圳 市理邦精密仪器股份有限公司（下称"公司"）的委托，指派律师出席公司 2024 年度股东大会（下称"本次股东大会"），并就本次股东大会的召集和召开程序、 召集人资格、出席和列席会议人员资格、表决程序及表决结果等事宜发表法律意 见。 为出具本法律意见书，本所律师审查了公司本次股东大会的有关文件和材料。 本所律师得到公司如下保证，即其已提供了本所律师认为出具本法律意见书所必 需的材料，所提供的原始材料、副本、复印件等材料和口头证言均符合真实、准 确、完整的要求，有关副本、复印件等材料与原始材料一致。 本法律意见书仅就本次股东大会的召集和召开程序是否符合法律、行政法规 及《公司章程》的规定，以及出席、列席本次股东大会人员的资格、召集人资格、 会议表决程序及表 ...

Company Overview - The company, Shenzhen Lifetech Scientific Corporation, closed at 11.91 yuan, with a 1.19% increase, and a rolling PE ratio of 36.59, marking a new low in 24 days, with a total market capitalization of 6.904 billion yuan [1] - The main business of the company involves the research, production, sales, and service of medical electronic devices and in vitro diagnostic products [1] Financial Performance - For the first quarter of 2025, the company reported an operating income of 420 million yuan, a year-on-year decrease of 5.25%, and a net profit of 65.0882 million yuan, reflecting a year-on-year increase of 68.98% [2] - The sales gross margin stood at 58.34% [2] Industry Comparison - The average PE ratio for the medical device industry is 49.84, with a median of 36.59, placing the company at the 75th position in the industry ranking [1][2] - The company's PE (TTM) is 36.59, while the static PE is 42.59, and the price-to-book ratio is 3.33 [2]

Core Insights - The company, Lifesense Medical, closed at 11.77 yuan, down 1.09%, with a rolling PE ratio of 36.16 times and a total market capitalization of 6.823 billion yuan [1][2] - The average PE ratio in the medical device industry is 48.98 times, with a median of 36.16 times, placing Lifesense Medical at the 75th position in the industry ranking [1][2] - As of April 10, 2025, the number of shareholders for Lifesense Medical is 28,143, a decrease of 288 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Financial Performance - In the first quarter of 2025, the company reported operating revenue of 420 million yuan, a year-on-year decrease of 5.25%, while net profit reached 65.0882 million yuan, reflecting a year-on-year increase of 68.98% [2] - The sales gross margin for the company stands at 58.34% [2] Industry Comparison - Lifesense Medical's PE (TTM) is 36.16, while the industry average is 48.98 and the industry median is 36.16 [2] - The company’s market capitalization is 6.823 billion yuan, compared to the industry average of 10.417 billion yuan and the industry median of 4.618 billion yuan [2]

关于召开 2024 年度股东大会的提示性公告 证券代码：300206 证券简称：理邦仪器 公告编号：2025-026 深圳市理邦精密仪器股份有限公司 关于召开2024年度股东大会的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市理邦精密仪器股份有限公司（以下简称"公司"）第五届董事会 2025 年 第一次会议决定于 2025 年 5 月 15 日（星期四）在深圳市坪山区坑梓街道金沙社 区金辉路 15 号理邦仪器工业园会议室召开 2024 年度股东大会，具体内容详见公 司于 2025 年 4 月 24 日在巨潮资讯网（www.cninfo.com.cn）披露的《关于召开 2024 年度股东大会的通知》，现将本次会议的有关事项提示如下： 一、召开会议的基本情况 1、 股东大会届次：2024 年度股东大会 2、 股东大会的召集人：公司第五届董事会 3、会议召开的合法、合规性： 公司于 2025 年 4 月 23 日召开的第五届董事会 2025 年第一次会议审议通过 了《关于提请召开 2024 年度股东大会》的议案，本次会议的召开程序符合有关 法律法 ...

Group 1 - The core viewpoint of the articles highlights the performance and market position of the company, Libang Instrument, within the medical device industry, noting its stock price, market capitalization, and financial metrics [1][2] - As of May 6, the stock price of Libang Instrument closed at 11.85 yuan, with a PE ratio of 36.41, which is the lowest in the past 20 days, and a total market value of 6.869 billion yuan [1] - The average PE ratio for the medical device industry is 48.90, with a median of 36.41, placing Libang Instrument at the 75th position in the industry ranking [1][2] Group 2 - For Q1 2025, the company reported an operating income of 420 million yuan, a year-on-year decrease of 5.25%, while net profit reached 65.0882 million yuan, reflecting a year-on-year increase of 68.98% [2] - The company's gross profit margin stands at 58.34%, indicating a strong profitability despite the decline in revenue [2] - The main business of Libang Instrument includes the research, production, sales, and service of medical electronic devices and in vitro diagnostic products, with a diverse range of offerings [1]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of the company, Ribang Instrument, within the medical device industry, noting its recent stock price increase and market capitalization [1][2] - As of April 30, Ribang Instrument's closing price was 11.68 yuan, reflecting a 2.01% increase, with a rolling PE ratio of 35.88, marking a new low in 19 days, and a total market value of 6.77 billion yuan [1] - The average PE ratio for the medical device industry is 48.11, with a median of 35.88, positioning Ribang Instrument at the 75th rank within the industry [1][2] Group 2 - For the first quarter of 2025, Ribang Instrument reported an operating income of 420 million yuan, representing a year-on-year decrease of 5.25%, while net profit reached 65.09 million yuan, showing a significant increase of 68.98% [2] - The company's gross profit margin stands at 58.34%, indicating a strong profitability despite the decline in revenue [2] - As of the first quarter of 2025, two institutions held shares in Ribang Instrument, with a total holding of 48.78 million shares valued at 591 million yuan [1]

Financial Performance - In Q1 2025, the company achieved a revenue of 420 million CNY, a decrease of approximately 5% year-on-year [3] - Domestic sales revenue was 166 million CNY, down about 20% year-on-year, while international sales revenue was 254 million CNY, up approximately 7% [3] - The overall gross margin for 2024 reached 57.92%, showing an improvement due to an increase in high-margin product sales [8] Market Outlook - The company maintains an optimistic outlook for domestic sales growth in 2025, anticipating recovery in market demand and the introduction of competitive new products [3] - The overseas patient monitoring business is expected to grow at a double-digit rate, with positive performance in Q1 2025 [11] AI Integration - The company established an AI-focused organization in March 2025, aiming to enhance efficiency and create value in ultrasound imaging and smart healthcare [4] - AI applications have significantly reduced examination times and improved patient flow management in emergency settings [4] Supply Chain and Tariff Impact - Components imported from the U.S. account for approximately 0-10% of the main product costs, with ongoing adjustments to ensure supply chain stability amid tariff uncertainties [9] - The company has initiated capacity expansion for its U.S. subsidiary to mitigate the impact of increased tariffs, with completion expected by June 2025 [7] Product Development and Strategy - The i500 wet blood gas product has been cautiously promoted since Q4 2024, with a focus on long-term market leadership and customer satisfaction [12] - The company is actively monitoring the impact of price reductions in IVD products due to centralized procurement policies, which have limited effects on its business [14] Inventory Management - By the second half of 2024, domestic channel inventory levels have returned to normal, allowing for a more stable sales environment [13] - The company has optimized its internal sales team to enhance competitiveness in the domestic market [7] Health Care Product Promotion - The domestic market strategy for personal health care products includes leveraging e-commerce platforms and extending the company's strong brand influence in obstetrics [15]